EPCAM and cancer: It is worth noting that underivatized mAb may not be sufficient for effective cancer therapy; as reflected in our findings, alternative approaches such as bispecific anti-EpCAM/anti-CD3 antibodies and ADCs face challenges with stability, specificity, and toxicity in clinical trials.